Close Asset Management’s AstraZeneca AZN Stock Holding History

Close Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,025	Closed	-$188K	–	269
2025 Q4	$188K	Hold	1,025	–	–	﹤0.01%	133
2025 Q3	$157K	Hold	1,025	–	–	﹤0.01%	134
2025 Q2	$143K	Hold	1,025	–	–	﹤0.01%	134
2025 Q1	$151K	Sell	1,025 -175	-15%	-$25.3K	﹤0.01%	129
2024 Q4	$157K	Hold	1,200	–	–	﹤0.01%	127
2024 Q3	$187K	Hold	1,200	–	–	0.01%	123
2024 Q2	$187K	Hold	1,200	–	–	0.01%	124
2024 Q1	$163K	Hold	1,200	–	–	0.01%	125
2023 Q4	$162K	Hold	1,200	–	–	0.01%	121
2023 Q3	$163K	Hold	1,200	–	–	0.01%	115
2023 Q2	$172K	Hold	1,200	–	–	0.01%	114
2023 Q1	$167K	Hold	1,200	–	–	0.01%	106
2022 Q4	$163K	Hold	1,200	–	–	0.01%	92
2022 Q3	$132K	Hold	1,200	–	–	0.01%	99
2022 Q2	$159K	Sell	1,200 -30	-2%	-$3.94K	0.01%	99
2022 Q1	$143K	Hold	1,230	–	–	0.01%	95
2021 Q4	$143K	Hold	1,230	–	–	0.01%	95
2021 Q3	$148K	Hold	1,230	–	–	0.01%	93
2021 Q2	$147K	Buy	1,230 +30	+3%	+$3.29K	0.01%	102
2021 Q1	$119K	Buy	+1,200	New	+$121K	0.01%	111

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Close Asset Management's AZN Position: Q1 2026 in Review

Close Asset Management sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 1,025 shares — an estimated $188K sold.

Close Asset Management first reported a position in AZN in Q1 2021 and held it in 20 quarters. The position peaked at $188K in Q4 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Close Asset Management reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
Close Asset Management sold 1,025 AstraZeneca shares in Q1 2026, an estimated $188K.
Close Asset Management first reported a position in AstraZeneca in Q1 2021 and held it in 20 quarters.
Close Asset Management's AstraZeneca position peaked at $188K in Q4 2025.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Close Asset Management's 13F filing for Q1 2026, filed 12 May 2026.